title: Acute rejection of lung allografts with various immunosuppressive protocols.
abstract: Between February 1990 and December 1991, 69 patients who survived for a minimum of 5 days after single-lung (27), double-lung (32), or heart-lung transplantation (10) were studied to learn the incidence and severity of acute rejection and the possible effects of various immunosuppressive protocols on this rejection. Acute rejection was less common (2.1 versus 3.1 episodes/patient) after transplantation in those 30 candidates who received rabbit antithymocyte globulin for the first 5 postoperative days versus the 28 who were maintained on cyclosporine, azathioprine, and prednisone alone (p < 0.05), but no patient escaped at least one episode. Patients given cyclosporine received more 3-day courses of methylprednisolone (p < 0.02) than those given rabbit antithymocyte globulin (2.5 versus 1.7 courses). Although no disadvantage in terms of infectious morbidity was noted in the rabbit antithymocyte globulin group, no obvious intermediate advantage was noted in survival (85% at 12 months) or grade of rejection or airway flows. The most common histopathologic grades were mild (A2) and moderate (A3); the average grade was A2.3. FK 506 was tested in 11 patients, and early results are promising relative to low early and likely fewer late episodes of rejection. No differences were noted in the likelihood of rejection for any procedures.
authors.affiliation: Department of Surgery, University of Pittsburgh School of Medicine, Pennsylvania 15261.
authors.forename: B P
authors.initials: BP
authors.lastname: Griffith
authors.forename: R L
authors.initials: RL
authors.lastname: Hardesty
authors.forename: J M
authors.initials: JM
authors.lastname: Armitage
authors.forename: R L
authors.initials: RL
authors.lastname: Kormos
authors.forename: G C
authors.initials: GC
authors.lastname: Marrone
authors.forename: S
authors.initials: S
authors.lastname: Duncan
authors.forename: I
authors.initials: I
authors.lastname: Paradis
authors.forename: J H
authors.initials: JH
authors.lastname: Dauber
authors.forename: S A
authors.initials: SA
authors.lastname: Yousem
authors.forename: P
authors.initials: P
authors.lastname: Williams
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000961:Antilymphocyte Serum / Q000008:administration & dosage; D001379:Azathioprine / Q000008:administration & dosage; D001707:Biopsy, Needle; D002648:Child; D016572:Cyclosporine / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000473:pathology; D016041:Heart-Lung Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008168:Lung / Q000473:pathology; D016040:Lung Transplantation / Q000401:mortality; D008875:Middle Aged; D011183:Postoperative Complications; D011241:Prednisone / Q000008:administration & dosage; D015996:Survival Rate
chemical_list: D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D001379:Azathioprine; D011241:Prednisone